Raymond James maintains AbbVie stock Outperform with $218 target
James analyst Gary Nachman maintained an Outperform rating on AbbVie stock (NYSE:ABBV) with a $218.00 price target. The ...
Stargate Project’s healthcare winners: AI-led biotechs and Metagenomi
The Stargate Project, a $500B initiative focused on artificial intelligence, lifted AI-driven biotech stocks this week while boosting an unlikely winner, Metagenomi (NASDAQ:MGX), which benefitted from ...